Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2023
2022
2021
2020
2019
2018
2017
Nov 30, 2023
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial
➞
Nov 28, 2023
Mabwell Partners with Innobic (Asia) Co., Ltd. to Market its products in Thailand
➞
Nov 16, 2023
Mabwell Announces the Appointment of Dr. Hai Wu as the President of R&D
➞
Oct 30, 2023
Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Argentina Market
➞
Oct 25, 2023
Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell’s 9MW2821 at 2023 ESMO
➞
Oct 23, 2023
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs
➞
Sep 27, 2023
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
➞
Sep 26, 2023
Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador
➞
Sep 22, 2023
FDA Grants Fast Track Designation to 9MW3011
➞
Sep 06, 2023
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics
➞
1
2
3
4
下一页
aoa体育电竞官网
|
中国体育竞猜网
|
亚虎集团(中国)有限公司官网
|
爱发体育|(中国)股份有限公司
|
永利欢乐娱人城
|
BOB官方网站(中国)BOB有限公司
|
新2体育官网(集团)有限公司
|
万博
|
kok电竞官方网站(中国)有限公司
|